LIGAND PHARMACEUTICAL INC (LGNXZ)
USD 0.0
(-63.33%)
USD 0.0
(-63.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 88.02 Million USD | -26.12% |
| 2022 | 119.14 Million USD | -17.98% |
| 2021 | 145.27 Million USD | 11.5% |
| 2020 | 130.28 Million USD | 95.32% |
| 2019 | 66.7 Million USD | -70.91% |
| 2018 | 229.32 Million USD | 85.51% |
| 2017 | 123.61 Million USD | 33.27% |
| 2016 | 92.75 Million USD | 40.32% |
| 2015 | 66.1 Million USD | 2.43% |
| 2014 | 64.53 Million USD | 31.78% |
| 2013 | 48.97 Million USD | 56.02% |
| 2012 | 31.38 Million USD | 4.5% |
| 2011 | 30.03 Million USD | 27.61% |
| 2010 | 23.53 Million USD | -39.55% |
| 2009 | 38.94 Million USD | 42.56% |
| 2008 | 27.31 Million USD | 111.84% |
| 2007 | 12.89 Million USD | -89.1% |
| 2006 | 118.31 Million USD | -13.49% |
| 2005 | 136.76 Million USD | 150.66% |
| 2004 | 54.56 Million USD | -50.18% |
| 2003 | 109.52 Million USD | 43.48% |
| 2002 | 76.33 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 30.36 Million USD | 52.53% |
| 2024 Q1 | 19.91 Million USD | 9.73% |
| 2023 Q1 | 32.1 Million USD | 58.38% |
| 2023 Q3 | 21.21 Million USD | 27.85% |
| 2023 Q2 | 16.59 Million USD | -48.31% |
| 2023 Q4 | 18.14 Million USD | -14.47% |
| 2023 FY | 88.02 Million USD | -26.12% |
| 2022 Q2 | 33.41 Million USD | 14.46% |
| 2022 Q3 | 40.08 Million USD | 19.98% |
| 2022 Q1 | 29.19 Million USD | -40.07% |
| 2022 FY | 119.14 Million USD | -17.98% |
| 2022 Q4 | 20.26 Million USD | -49.44% |
| 2021 Q1 | 34.68 Million USD | -77.77% |
| 2021 Q3 | 41.56 Million USD | -2.49% |
| 2021 Q2 | 42.62 Million USD | 22.9% |
| 2021 Q4 | 48.71 Million USD | 17.21% |
| 2021 FY | 145.27 Million USD | 11.5% |
| 2020 Q2 | 41.42 Million USD | 24.91% |
| 2020 FY | 130.28 Million USD | 95.32% |
| 2020 Q3 | 41.84 Million USD | 1.03% |
| 2020 Q4 | 156 Million USD | 272.78% |
| 2020 Q1 | 33.16 Million USD | 0.0% |
| 2019 Q2 | 24.98 Million USD | -42.54% |
| 2019 FY | 66.7 Million USD | -70.91% |
| 2019 Q1 | 43.48 Million USD | 0.0% |
| 2019 Q3 | 24.8 Million USD | -0.72% |
| 2018 Q3 | 44.2 Million USD | -50.28% |
| 2018 Q2 | 88.9 Million USD | 60.58% |
| 2018 FY | 229.32 Million USD | 85.51% |
| 2018 Q1 | 55.36 Million USD | 0.0% |
| 2017 Q2 | 27.09 Million USD | -6.34% |
| 2017 FY | 123.61 Million USD | 33.27% |
| 2017 Q3 | 30.99 Million USD | 14.39% |
| 2017 Q1 | 28.92 Million USD | 0.0% |
| 2016 Q2 | 15.81 Million USD | -44.87% |
| 2016 Q1 | 28.69 Million USD | 0.0% |
| 2016 Q3 | 20.62 Million USD | 30.36% |
| 2016 FY | 92.75 Million USD | 40.32% |
| 2015 FY | 66.1 Million USD | 2.43% |
| 2015 Q3 | 17.7 Million USD | -3.89% |
| 2015 Q2 | 18.41 Million USD | 36.15% |
| 2015 Q1 | 13.52 Million USD | 0.0% |
| 2014 Q3 | 13.47 Million USD | 43.04% |
| 2014 FY | 64.53 Million USD | 31.78% |
| 2014 Q1 | 13.5 Million USD | 0.0% |
| 2014 Q2 | 9.42 Million USD | -30.24% |
| 2013 Q3 | 10.46 Million USD | 25.11% |
| 2013 Q2 | 8.36 Million USD | -23.86% |
| 2013 Q1 | 10.98 Million USD | 0.0% |
| 2013 FY | 48.97 Million USD | 56.02% |
| 2012 FY | 31.38 Million USD | 4.5% |
| 2012 Q2 | 5.3 Million USD | -3.17% |
| 2012 Q3 | 5.69 Million USD | 7.25% |
| 2012 Q1 | 5.48 Million USD | 0.0% |
| 2011 Q1 | 3.37 Million USD | 0.0% |
| 2011 Q2 | 5.84 Million USD | 73.24% |
| 2011 FY | 30.03 Million USD | 27.61% |
| 2011 Q3 | 5.03 Million USD | -13.73% |
| 2010 FY | 23.53 Million USD | -39.55% |
| 2010 Q3 | 7.8 Million USD | 33.64% |
| 2010 Q2 | 5.83 Million USD | -2.01% |
| 2010 Q1 | 5.95 Million USD | 0.0% |
| 2009 Q1 | 9.47 Million USD | 0.0% |
| 2009 FY | 38.94 Million USD | 42.56% |
| 2009 Q2 | 7.59 Million USD | -19.81% |
| 2009 Q3 | 7.9 Million USD | 4.04% |
| 2008 Q3 | 5.24 Million USD | 9.24% |
| 2008 Q2 | 4.8 Million USD | -1.44% |
| 2008 Q1 | 4.87 Million USD | 0.0% |
| 2008 FY | 27.31 Million USD | 111.84% |
| 2007 FY | 12.89 Million USD | -89.1% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | 1.41 Million USD | 0.0% |
| 2007 Q3 | 5.47 Million USD | 288.58% |
| 2006 Q1 | 41.21 Million USD | 0.0% |
| 2006 Q2 | 38.18 Million USD | -7.36% |
| 2006 Q3 | 30.9 Million USD | -19.05% |
| 2006 FY | 118.31 Million USD | -13.49% |
| 2005 FY | 136.76 Million USD | 150.66% |
| 2005 Q2 | 35.13 Million USD | 35.54% |
| 2005 Q1 | 25.92 Million USD | 0.0% |
| 2005 Q3 | 34.94 Million USD | -0.52% |
| 2004 FY | 54.56 Million USD | -50.18% |
| 2004 Q1 | 27.78 Million USD | 0.0% |
| 2004 Q2 | 30.53 Million USD | 9.88% |
| 2003 FY | 109.52 Million USD | 43.48% |
| 2003 Q2 | 21.36 Million USD | 29.43% |
| 2003 Q1 | 16.5 Million USD | 0.0% |
| 2003 Q3 | 22.71 Million USD | 6.36% |
| 2002 Q3 | 25.26 Million USD | 0.0% |
| 2002 FY | 76.33 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | - USD | -Infinity% |
| Allstar Health Brands, Inc. | - USD | -Infinity% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 134.07 Million USD | 34.347% |
| Café Serendipity Holdings, Inc. | 1196.00 USD | -7359933.445% |
| Decision Diagnostics Corp. | - USD | -Infinity% |
| Health Advance Inc. | - USD | -Infinity% |
| HealthWarehouse.com, Inc. | 12.17 Million USD | -623.07% |
| MedGen, Inc. | 1.05 USD | -8383428471.429% |
| Omni Health, Inc. | 1.55 Million USD | -5569.795% |
| Oxford Investments Holdings Inc. | 31.45 Thousand USD | -279720.713% |
| Pineapple, Inc. | -1.02 Million USD | 8690.484% |
| ScripsAmerica, Inc. | 27.59 Million USD | -218.968% |